催化劑製藥 CPRX 深 滬
交易中 04-01 11:53:31 美东时间
24.97
+0.210
+0.85%
華盛通- 最 高25.14
- 今 開25.00
- 成交量 34.54万股
- 最 低 24.745
- 昨 收 24.76
- 總市值 30.49亿
- 52周最高 26.58
- 市盈率 靜 14.83
- 換手率 0.28%
- 52周最低 19.05
- 委 比 98.63%
- 總股本 1.22亿
- 歷史最高 26.58
- 量 比 1.21
- 振 幅 1.60%
- 歷史最低 0.37
- 每 手 1
- 風險率 1.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Catalyst Pharmaceuticals Says District Court Delays Bench Trial To May 18, 2026; Bench Trial Concerns Validity Of FIRDAPSE Patents Expiring In 2032, 2034, 2037
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001369568/000119312526114306/d111324d8k.htm
03-19 05:45
Catalyst Pharma To Showcase Real‑World Findings In Duchenne Muscular Dystrophy Through Multiple Poster Presentations At 2026 MDA Clinical & Scientific Conference
Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and
03-06 21:09
**Catalyst to present DMD real‑world findings at 2026 MDA Clinical & Scientific Conference**
**Catalyst to present DMD real‑world findings at 2026 MDA Clinical & Scientific Conference** Catalyst Pharmaceuticals (CPRX) will present three Duchenne muscular dystrophy real-world posters at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida, on March 8, 2026 (6:00–8:00 PM ET). The
03-06 21:03
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
Catalyst Pharmaceuticals will present real-world findings on vamorolone in Duchenne muscular dystrophy (DMD) at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. The company will showcase three poster presentations focusing on vamorolone's safety, healthcare resource utilization, and respiratory outcomes. Additionally, Catalyst will sponsor an MDA Industry Forum with Santhera Pharmaceuticals, featuring insights from clinical lead...
03-06 13:03
财报速睇 | 催化剂制药 2025财年年度营收5.89亿美元，同比增长19.8%；归母净利润2.14亿美元，同比增长30.8%
华盛资讯2月26日讯，催化剂制药公布2025财年年度业绩，公司年度营收5.89亿美元，同比增长19.8%，归母净利润2.14亿美元，同比增长30.8%。
02-26 09:20
财报速睇 | 催化剂制药 2025财年Q4营收1.53亿美元，同比增长7.6%；归母净利润0.53亿美元，同比下滑5.8%
华盛资讯2月26日讯，催化剂制药公布2025财年Q4业绩，公司Q4营收1.53亿美元，同比增长7.6%，归母净利润0.53亿美元，同比下滑5.8%。
02-26 06:05
Earnings Scheduled For February 25, 2026
Companies Reporting Before The Bell • Clear Secure (NYSE:YOU) is expected to re...
02-25 19:11
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
Catalyst Pharmaceuticals CEO Rich Daly and management team will participate in the Barclays Global Healthcare Conference on March 10, 2026, in Miami. They will present at 3:30 PM ET, and a webcast will be available on the Company’s website, www.catalystpharma.com, with a replay accessible for 30 days. Catalyst, a biopharmaceutical company focused on rare diseases, has a strong U.S. presence and a track record of successful commercialization. The ...
02-24 13:03
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
Catalyst Pharmaceuticals will release its 2025 Q4 and full-year financial results on February 25, 2026, after market close. A conference call and webcast to discuss the results and provide a business update will be held on February 26, 2026, at 8:30 AM ET. The event will be accessible via dial-in numbers and live webcast on the company's website, with a replay available for 30 days.
02-11 13:03
Jim Cramer: Crane Is A 'Good' Company, Recommends Holding This Tech Stock
Jim Cramer recommended holding Texas Instruments (TXN) on CNBC's Mad Money, supported by an analyst's hold rating and raised price target. He also praised Crane Company (CR) and Catalyst Pharmaceuticals (CPRX) for their strong earnings.
01-15 01:26
